drugset / Trial / NCT06218823

Tobacco Treatment Comparison for Cancer Care

NCT06218823

RandomizedParallel-groupOpen-labelTreatment

Summary

This pilot comparative effectiveness trial will compare two active smoking cessation treatments in terms of effectiveness, equity across patient subpopulations, and efficiency among adult patients diagnosed with cancer within the past 3 years. An enhanced treatment comprising 12 weeks of varenicline treatment and 7 smoking cessation coaching calls with a cancer focus will be compared against an active comparator modeled after standard quitline treatments (2 weeks of nicotine patch therapy with 3 phone coaching calls). Approximately 50 participants will be recruited to generate estimates of the effects, acceptability, costs, and equity of enhanced treatment (vs. standard treatment), with the primary outcome being abstinence from smoking 26 weeks after trying to quit.

Timeline

Start
2024-03-01
Primary completion
2025-08-04
Completion
2025-08-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Transdermal Nicotine Patch Unknown 7 mg Other
Comparator Transdermal Nicotine Patch Unknown 14 mg Other
Comparator Transdermal Nicotine Patch Unknown 21 mg Other
Subject Varenicline Small molecule Oral

Indications